ALX Oncology raises $105m to advance clinical development of ALX148
ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity financing round led by Vivo Capital. The US biotech company is focused on developing therapies to block the CD47 checkpoint mechanism. ALX Oncology will use the Series C proceeds to help expand the clinical development of its […]